The importance of rare disease-specific procedures in HTA processes in ensuring equitable access to orphan products as a result of EU JCA

Previous PostVignette-Based Economic Models in NICE Submissions: A Two-Year Review
Next PostAssociation between caregiver quality of life and the care provided to adults with severe visual impairments in rare disease: A systematic review